Harnessing STING Signaling and Natural Killer Cells overcomes PARP Inhibitor Resistance in Homologous Recombination Deficient Breast Cancer
Cancer Res. 2025 Mar 11. doi: 10.1158/0008-5472.CAN-24-2531.…
Unraveling the power of NAP-CNB’s machine learning-enhanced tumor neoantigen prediction
Elife. 2025 Mar 11;13:RP95010. doi: 10.7554/eLife.95010.ABSTRACTIn…
Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment
NAR Cancer. 2025 Mar 7;7(1):zcaf007. doi: 10.1093/narcan/zcaf007.…
Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment
NAR Cancer. 2025 Mar 7;7(1):zcaf007. doi: 10.1093/narcan/zcaf007.…
Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment
NAR Cancer. 2025 Mar 7;7(1):zcaf007. doi: 10.1093/narcan/zcaf007.…
Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment
NAR Cancer. 2025 Mar 7;7(1):zcaf007. doi: 10.1093/narcan/zcaf007.…
Mitochondrial priming and response to BH3 mimetics in “one-two punch” senogenic-senolytic strategies
Cell Death Discov. 2025 Mar 7;11(1):91. doi: 10.1038/s41420-025-02379-y.ABSTRACTA…
Mitochondrial priming and response to BH3 mimetics in “one-two punch” senogenic-senolytic strategies
Cell Death Discov. 2025 Mar 7;11(1):91. doi: 10.1038/s41420-025-02379-y.ABSTRACTA…
Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer
Neoplasia. 2025 Feb 24;62:101143. doi: 10.1016/j.neo.2025.101143.…
A Novel RHEB Germline Variant Associated With Intellectual Disability and Epilepsy: Expanding the Spectrum of mTORopathies
Clin Genet. 2025 Feb 24. doi: 10.1111/cge.14734. Online ahead…
Clinical-genomic profiling of MDS to inform allo-HSCT:Recommendations from an international panel on behalf of the EBMT
Blood. 2025 Feb 19:blood.2024025131. doi: 10.1182/blood.2024025131.…
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
Clin Cancer Res. 2025 Feb 17;31(4):659-666. doi: 10.1158/1078-0432.CCR-24-2636.ABSTRACTPURPOSE:…
